Literature DB >> 32016030

Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC).

John T Isaacs1,2, W Nathaniel Brennen1,2, Samuel R Denmeade1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32016030      PMCID： PMC6976443          DOI： 10.21037/atm.2019.10.32

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Authors:  Hung-Ming Lam; Holly M Nguyen; Mark P Labrecque; Lisha G Brown; Ilsa M Coleman; Roman Gulati; Bryce Lakely; Daniel Sondheim; Payel Chatterjee; Brett T Marck; Alvin M Matsumoto; Elahe A Mostaghel; Michael T Schweizer; Peter S Nelson; Eva Corey
Journal:  Eur Urol       Date:  2019-06-19       Impact factor: 20.096

2.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

3.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Authors:  Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

4.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

5.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

6.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Authors:  Shuai Gao; Yanfei Gao; Housheng Hansen He; Dong Han; Wanting Han; Amy Avery; Jill A Macoska; Xiaming Liu; Sen Chen; Fen Ma; Shaoyong Chen; Steven P Balk; Changmeng Cai
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

7.  Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target?

Authors:  Michael C Haffner; Angelo M De Marzo; Alan K Meeker; William G Nelson; Srinivasan Yegnasubramanian
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

8.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

9.  Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.

Authors:  E G Langeler; C J van Uffelen; M A Blankenstein; G J van Steenbrugge; E Mulder
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

Authors:  J Kokontis; K Takakura; N Hay; S Liao
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701
View more
  3 in total

1.  Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.

Authors:  Michael C Haffner; Akshay Bhamidipati; Harrison K Tsai; David M Esopi; Ajay M Vaghasia; Jin-Yih Low; Radhika A Patel; Gunes Guner; Minh-Tam Pham; Nicole Castagna; Jessica Hicks; Nicolas Wyhs; Ruedi Aebersold; Angelo M De Marzo; William G Nelson; Tiannan Guo; Srinivasan Yegnasubramanian
Journal:  Prostate       Date:  2021-08-16       Impact factor: 4.104

2.  The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.

Authors:  Kimia Mirzakhani; Julia Kallenbach; Seyed Mohammad Mahdi Rasa; Federico Ribaudo; Martin Ungelenk; Marzieh Ehsani; Wenrong Gong; Nikolaus Gassler; Mirjam Leeder; Marc-Oliver Grimm; Francesco Neri; Aria Baniahmad
Journal:  Oncogene       Date:  2021-10-19       Impact factor: 9.867

3.  Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.

Authors:  Nicola J Nasser
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.